MedPath

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)

Phase 2
Not yet recruiting
Conditions
Lung Cancer
Metastatic NSCLC - Non-Small Cell Lung Cancer
Advanced NSCLC
NSCLC Stage IV
Interventions
Registration Number
NCT05859217
Lead Sponsor
Jun Zhang, MD, PhD
Brief Summary

NSCLC patients with low expression level of PD-L1, esp. those with its level less than 1%, do not derive much benefit from anti-PD-1/L1 therapy (e.g. atezoilzumab). In this study, investigators hypothesize that the combination of cabozantinib (a multi-kinase inhibitor) and atezolizumab will result in better therapeutic value.

Detailed Description

For metastatic/advanced non-small cell (NSCLC) patients who do not have targetable mutations, the combination of chemotherapy with immunotherapy targeting the programmed death-1 and its ligand (PD-1/L1) is now a standard of care. In addition, recent studies also demonstrated that immunotherapy doublet using anti-PD-1 agent nivolumab and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) agent ipilimumab could be another valid option. However, largely due to the immunosuppressive tumor microenvironment, the therapeutic response remains suboptimal in NSCLC patients with PD-L1 tumor proportion score (TPS) lower than 1% (aka PD-L1 negative). For example, the objective response rate (ORR) in KEYNOTE-189 was 32.3% using pembrolizumab plus chemotherapy, and only 27.3% in Checkmate 227 study using nivolumab and ipilimumab, in the PD-L1 negative population. These observations necessitate the search for novel combinations to benefit our PD-L1 negative NSCLC patients.

The investigators hypothesize that the combination of cabozantinib and atezolizumab is such an innovative strategy based on the following rationales: 1) cabozantinib is a multi-kinase inhibitor, and some of the targets, for example the vascular endothelial growth factor (VEGF) pathway is notorious to confer immune suppressive tumor microenvironment. In fact, our previous study has demonstrated that anti-VEGF synergizes anti-PD-1 in preclinical model. Consistent with this, cabozantinib has been shown to increase tumor infiltrative cytotoxic CD8+ T cells, reduce immune suppressive T regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs), as well as activate anti-tumor innate immunity in multiple solid tumors; 2) at the animal level, cabozantinib was found synergistic with anti-PD-1 agents to elicit anti-tumor immune response; and 3) more importantly, at the human level, the combination of cabozantinib with atezolizumab was found safe in Cohort 7 of the phase 1b COSMIC-021 study and achieved 27% ORR in previously immunotherapy-treated NSCLC - suggesting a potentially higher efficacy if such combination is to be used in the 1st line setting.

The investigators therefore propose here the combination of cabozantinib and atezolizumab to be used as the 1st line treatment for advanced/metastatic NSCLC with negative PD-L1 expression.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Cabozantinib and AtezolizumabCabozantinibCabozantinib 40mg po daily + Atezolizumab 1200mg iv on day 1; 1 cycle = 21 days
Cabozantinib and AtezolizumabAtezolizumabCabozantinib 40mg po daily + Atezolizumab 1200mg iv on day 1; 1 cycle = 21 days
Primary Outcome Measures
NameTimeMethod
Objective response rate (ORR)through study completion, an average of 1 year

From baseline to End of Treatment (EOT) due to disease progression using RECIST criteria 1.1

Secondary Outcome Measures
NameTimeMethod
Overall survival (OS)From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

Medical Record will be followed to watch survival status

Drug SafetyFrom date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

Safety of drugs will be determined by documenting adverse events and the severity of adverse events will be documented using CTCAE Version 5.0

Duration of response (DOR)From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

The response to the study drugs will be determined using RECIST criteria 1.1

Progression-free survival (PFS)From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

The lack of progression will be dertermined using RECIST criteria 1.1

Trial Locations

Locations (4)

The University of Kansas Cancer Center - Westwood

🇺🇸

Kansas City, Kansas, United States

The University of Kansas Cancer Center - Indian Creek

🇺🇸

Overland Park, Kansas, United States

The University of Kansas Cancer Center - Lee's Summit

🇺🇸

Lee's Summit, Missouri, United States

The University of Kansas Cancer Center - North

🇺🇸

Kansas City, Missouri, United States

© Copyright 2025. All Rights Reserved by MedPath